Here's a summary tailored to your preferences: **1. Financial Highlights:** Q1 FY26 revenue jumped 28% YoY to ₹1,403.8 Cr, outpacing industry growth.

Profit After Tax surged 47% to ₹30.2 Cr.

Gross margins expanded to 9.9% and EBITDA margins to 3.6%. Net Operating Working Capital remained stable at 66 days. **2. Strategic Initiatives & Growth Drivers:** Strategy focuses on consolidating the fragmented healthcare supply chain via organic growth and disciplined M&A. Expanding into new categories and driving efficiencies aims for profitable growth and improved return ratios. **3. Business Developments:** Entero's 28% Q1 FY26 revenue growth (vs. 9% IPM) indicates strong performance.

Expanded operational reach with 71,000+ retail customers and 102 warehouses.

Awarded "Excellence in Healthcare Supply Chain and Logistics- 2024." **4. Market Position & Competitive Advantage:** As a top-three Indian healthcare product distributor, Entero leverages its pan-India presence and proprietary technology.

Over 50 acquisitions enable rapid scale-up, providing a strong competitive edge in a consolidating market. **5. Investor Implications:** Strong Q1 results with outperformance and margin expansion signal positive growth potential.

Entero's disciplined M&A and operational efficiency in a large, consolidating market suggest a compelling investment.